Maddi Hebebrand, MC, Associate Editor

In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.

The review emphasizes that psychological stress can influence inflammatory pathways involved in CSU, potentially worsening disease activity.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

More than 35% of zasocitinib-treated patients reached complete skin clearance at week 16, with treatment curve separation emerging as early as week 8.

Findings support ongoing pharmacovigilance monitoring of GLP-1 receptor agonists for hair loss, particularly as semaglutide and tirzepatide use continues to expand.

Valerie Stern, DMSc, MPAS, PA-C, argues that dermatology conferences offer APPs something CME alone can't — a community that understands the specific professional pressures of the role.

The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.

From case reports to conference presentations, Stern outlines a practical path APPs can follow to build a profile beyond their day-to-day clinical role.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

As one of California's first derm PAs, Stern discusses the mentorship-driven private practice model that launched her career and its near-disappearance today.

Patients experiencing hormonal skin changes frequently report feeling unheard, and Doral Fredericks, PharmD, MBA, argues that active reassessment rather than attribution to aging is the clinical default that's needed.

Experts recommend routine genital assessment as part of comprehensive skin exams rather than relying on patient-initiated reporting of this sensitive manifestation.

Organon's Doral Fredericks, PharmD, MBA, explains why pregnancy and menopause remain chronically understudied in dermatology research and what clinicians are missing as a result.

Turn Therapeutics is preparing to request an FDA meeting to discuss regulatory strategy and potential pathways toward market following successful Phase 2 completion.

Unlike approved AD biologics and JAK inhibitors targeting specific cytokine pathways, GX-03 is designed to modulate inflammatory signaling locally within the skin microenvironment.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

In the Chair puts you in the hot spot, challenging you to navigate complex, real-world cases.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

This month’s podcasts highlight the latest clinical insights, emerging therapies, and evolving conversations shaping dermatology practice.

Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.

A review in JEADV Clinical Practice argues that deliberate nail examination in children can generate and narrow a differential diagnosis across virtually every organ system.

At 6-month follow-up, no behavioral outcomes — including sunscreen use, hat use, or reapplication — showed statistically significant improvement over baseline levels.

Apogee plans to initiate 3 phase 3 trials of zumilokibart in moderate to severe atopic dermatitis—ADventure 1, ADventure 2, and ADventure TCS—in the second half of 2026.

Among more than 1700 patients enrolled in the long-term extension study, the majority transitioned from a moderate to severe AD phenotype at baseline to a mild phenotype within 12 weeks, with that shift maintained through 2 years.

Dermatologists are increasingly integrating AI into clinical workflows, though many still use it primarily as a search tool rather than a true care-support system.

Clinical outcomes improved in both switch directions following treatment modification, with substantial reductions in PASI and EASI scores.

The findings suggest tetracycline activity may vary depending on drug concentration and local tissue exposure.